• Type: Private; Industry: Pharmaceutical industry; Founded: 1983; Headquarters: Lachen, Switzerland; Number of locations: 31; Products: octanate; octanine-F; wilate; Nuwiq;
    octagam; gammanorm; rhesonativ; panzyga; albunorm; octaplas; atenativ; octaplex; octaplasLG; fibryga; Revenue: Euro 2.8 billion (2022)[1]; Number of employees: 11,573(2022)[2] Therapeutic Areas Patients in 118 countries are treated with products
    in the following therapeutic areas: • Haematology: high-purity coagulation factor concentrates for patients with bleeding disorders Haemophilia A, B and von Willebrand Disease.

  • Products Octapharma medicines treat a broad range of rare and life-threatening congenital and acquired diseases and conditions: – bleeding disorders (hemophilia A / B and
    VWD) – over 300 types of primary and secondary immune deficiencies – numerous auto-immune and neurological disorders – acute conditions – critical care issues (including trauma and burn victims) – cancer patients – major surgeries – protection
    of new-borns in case of Rh negative pregnancies Production Octapharma converts source plasma into plasma protein products through fractionation and processing.

  • As of December 31, 2022, Octapharma employs around 10,000 people worldwide to support the treatment of patients in 118 countries with products across three therapeutic areas:
    Hematology, Immunotherapy and Critical Care.

  • Octapharma AG, founded in 1983, is a family-owned pharmaceutical company, and bills itself as “one of the largest human protein manufacturers in the world, developing and
    producing human proteins from human plasma and human cell lines[3].”

  • The underlying principle of Octapharma’s R&D is the development of therapies based on human proteins either purified from human plasma or produced by recombinant technologies
    applied to human cell lines.


Works Cited

[‘Annual report 2022 https://www.octapharma.com/news/press-release/2022/octapharma-group-delivers-strong-growth-in-sales-and-operating-income-in-2021/
2. ^ About us on https://www.octapharma.com/about-us/who-we-are
3. ^ Octapharma Website http://www.octapharma.com/en/patients/diseases-therapies.html
Photo credit: https://www.flickr.com/photos/maf04/6347846687/’]